Incidences of herpes zoster and postherpetic neuralgia in japanese adults aged 50 years and older from a Community-based prospective cohort study: The SHEZ study

Journal of Epidemiology

Volumn 25, Issue 10, 2015, Pages 617-625

  Takao, Yukiko ^a   Miyazaki, Yoshiyuki ^a   Okeda, Masayuki ^a   Onishi, Fumitake ^a   Yano, Shuichiro ^a   Gomi, Yasuyuki ^a   Ishikawa, Toyokazu ^a   Okuno, Yoshinobu ^a   Mori, Yasuko ^b   Asada, Hideo ^c   Yamanishi, Koichi ^a   Iso, Hiroyasu ^d  

^a OSAKA UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Herpes zoster; Incidence; Japanese adults; Postherpetic neuralgia; Prospective cohort study

Indexed keywords

AGE DISTRIBUTION; AGED; FEMALE; HERPES ZOSTER; HUMAN; INCIDENCE; JAPAN; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; PARTICIPATORY RESEARCH; PROSPECTIVE STUDY; RISK FACTOR; SEX RATIO; VERY ELDERLY;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; COMMUNITY-BASED PARTICIPATORY RESEARCH; FEMALE; HERPES ZOSTER; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; PROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION;

EID: 84958753206     PISSN: 09175040     EISSN: 13499092     Source Type: Journal    
DOI: 10.2188/jea.JE20140210     Document Type: Article

References (33)

1. Arvin AM. Varicella-zoster virus. Clin Microbiol Rev. 1996;9:361-81.
2. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster:recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57:1-30; quiz CE2-4.
3. Young MK, Wood M, Jean-Noel N. Postherpetic neuralgia in older adults: culture, quality of life, and the use of alternative/ complementary therapies. Holist Nurs Pract. 2007;21:124-34.
4. Takao Y, Miyazaki Y, Onishi F, Kumihashi H, Gomi Y, Ishikawa T, et al; SHEZ Study group. The Shozu Herpes Zoster (SHEZ) study: rationale, design, and description of a prospective cohort study. J Epidemiol. 2012;22:167-74.
5. Okuno Y, Takao Y, Miyazaki Y, Ohnishi F, Okeda M, Yano S, et al; Shozu Herpes Zoster (SHEZ) Study Group. Assessment of skin test with varicella-zoster virus antigen for predicting the risk of herpes zoster. Epidemiol Infect. 2013;141:706-13.
6. Sadaoka K, Okamoto S, Gomi Y, Tanimoto T, Ishikawa T, Yoshikawa T, et al. Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-linked immunospot assay. J Infect Dis. 2008;198:1327-33.
7. Shiraki K, Okuno T, Yamanishi K, Takahashi M. Polypeptides of varicella-zoster virus (VZV) and immunological relationship of VZV and herpes simplex virus (HSV). J Gen Virol. 1982;61(Pt 2):255-69.
8. Takahashi M, Okada S, Miyagawa H, Amo K, Yoshikawa K, Asada H, et al. Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay. Vaccine. 2003;21:3845-53.
9. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20:748-53.
10. Lin YH, Huang LM, Chang IS, Tsai FY, Lu CY, Shao PL, et al; Varicella-Zoster Working Group; Advisory Committee on Immunization Practices, Taiwan. Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan. Vaccine. 2010;28:1217-20.
11. Choi WS, Noh JY, Huh JY, Jo YM, Lee J, Song JY, et al. Disease burden of herpes zoster in Korea. J Clin Virol. 2010;47:325-9.
12. Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011;11:173.
13. Chen SY, Suaya JA, Li Q, Galindo CM, Misurski D, Burstin S,et al. Incidence of herpes zoster in patients with altered immune function. Infection. 2014;42:325-34.
14. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complications rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341-9.
15. Toyama N, Shiraki K; Society of the Miyazaki Prefecture Dermatologists. Epidemiology of herpes zoster and its relationship to varicella in Japan: a 10-year survey of 48 388 herpes zoster cases in Miyazaki Prefecture. J Med Virol. 2009;81:2053-8.
16. Gialloreti LE, Merito M, Pezzotti P, Naldi L, Gatti A, Beillat M, et al. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis. 2010;10:230.
17. Pierik JG, Gumbs PD, Fortanier SA, Van Steenwijk PC, Postma MJ. Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands. BMC Infect Dis. 2012;12:110.
18. Morant-Talamante N, Diez-Domingo J, Martínez-Úbeda S, Puig-Barberá J, Alemán-Sánchez S, Pérez-Breva L. Herpes zoster surveillance using electronic databases in the Valencian Community (Spain). BMC Infect Dis. 2013;13:463.
19. Fleming DM, Cross KW, Cobb WA, Chapman RS. Gender difference in the incidence of shingles. Epidemiol Infect. 2004;132:1-5.
20. Stein AN, Britt H, Harrison C, Conway EL, Cunningham A, Macintyre CR. Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine. 2009;27:520-9.
21. Weitzman D, Shavit O, Stein M, Cohen R, Chodick G, Shalev V. A population based study of the epidemiology of Herpes Zoster and its complications. J Infect. 2013;67:463-9.
22. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271-84.
23. Miller AE. Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology. 1980;30:582-7.
24. Burke BL, Steele RW, Beard OW, Wood JS, Cain TD, Marmer DJ. Immune responses to varicella-zoster in the aged. Arch Intern Med. 1982;142:291-3.
25. Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis. 2003;188:1336-44.
26. Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, et al; Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators. Varicellazoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008;197:825-35.
27. Weinberg A, Lazar AA, Zerbe GO, Hayward AR, Chan IS, Vessey R, et al. Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses. J Infect Dis. 2010;201:1024-30.
28. Tang H, Moriishi E, Okamoto S, Okuno Y, Iso H, Asada H, et al; Shozu Herpes Zoster Study group. A community-based survey of varicella-zoster virus-specific immune responses in theelderly. J Clin Virol. 2012;55:46-50.
29. Schmader K, George LK, Burchett BM, Pieper CF. Racial and psychosocial risk factors for herpes zoster in the elderly. J Infect Dis. 1998;178 Suppl 1:S67-70.
30. Heymann AD, Chodick G, Karpati T, Kamer L, Kremer E, Green MS, et al. Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection. 2008;36:226-30.
31. Lasserre A, Blaizeau F, Gorwood P, Bloch K, Chauvin P, Liard F, et al. Herpes zoster: family history and psychological stresscase- control study. J Clin Virol. 2012;55:153-7.
32. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults:a case-control study. Lancet. 2002;360:678-82.
33. Yih WK, Brooks DR, Lett SM, Jumaan AO, Zhang Z, Clements KM, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health. 2005;5:68.